Restricted accessResearch articleFirst published online 2026-1
Bone Marrow Mesenchymal Stem Cells Derived from Acute Myeloid Leukemia Patients Contribute to Leukemia Cell Survival Through Decorin/Matrix Metalloproteinase-2 Crosstalk
Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow. Despite advances in chemotherapy and targeted therapies, drug resistance and high relapse rates remain the major challenges in AML treatment. Accumulating evidence indicates that bone marrow mesenchymal stem cells (MSCs)-mediated microenvironment changes play a crucial role in the pathogenesis of AML and may contribute to the therapeutic challenges of current treatment strategies. In this study, we further characterized the role and revealed the molecular mechanism of AML-derived MSCs (AML-MSCs) in AML pathogenesis. We found that AML-MSCs significantly promoted AML cell proliferation and inhibited apoptosis, primarily through direct cell-to-cell contact. Bioinformatics analysis of multiple sequencing datasets revealed that decorin (DCN), encoding a core extracellular matrix protein, is significantly upregulated in AML-MSCs. DCN could enhance AML cell viability through functional interplay with matrix metalloproteinase-2 (MMP2) in AML cells. Both inhibition of DCN in AML-MSCs and MMP2 in AML cells significantly attenuated the supportive effect of AML-MSCs on AML cells. These findings provide novel insights into the role of MSC-mediated bone marrow microenvironment remodeling in AML pathogenesis and highlight DCN and MMP2 as potential therapeutic targets for AML treatment.
HanB, ZhengR, ZengH, et al.Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024; 4:47–53; doi: 10.1016/j.jncc.2024.01.006
2.
SaadhMJ, FardNT, HusseinA, et al.Mesenchymal stem cells in the bone marrow microenvironment: A double-edged sword for AML. J Cancer Res Clin Oncol, 2025; 151:193; doi: 10.1007/s00432-025-06244-4
3.
CheungHL, WongYH, LiYY, et al.Microenvironment matters: In vitro 3D bone marrow niches differentially modulate survival, phenotype and drug responses of acute myeloid leukemia (AML) cells. Biomaterials, 2025; 312:122719; doi: 10.1016/j.biomaterials.2024.122719
4.
von der HeideEK, NeumannM, VosbergS, et al.Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients. Leukemia, 2017; 31:1069–1078; doi: 10.1038/leu.2016.324
5.
BandyopadhyayS, DuffyMP, AhnKJ, et al.Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging. Cell, 2024; 187:3120–3140.e29; doi: 10.1016/j.cell.2024.04.013
6.
CorradiG, BaldazziC, OcadlikovaD, et al.Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. Stem Cell Res Ther, 2018; 9:271; doi: 10.1186/s13287-018-1013-z
7.
BenjaminESB, VinodE, IllangeswaranRSS, et al.Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSCs) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs. Cell Signal, 2024; 116:111067; doi: 10.1016/j.cellsig.2024.111067
8.
LopesMR, PereiraJK, de Melo CamposP, et al.De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes. Sci Rep, 2017; 7:40707; doi: 10.1038/srep40707
9.
PlakhovaN, PanagopoulosV, VandykeK, et al.Mesenchymal stromal cell senescence in haematological malignancies. Cancer Metastasis Rev, 2023; 42:277–296; doi: 10.1007/s10555-022-10069-9
10.
LaingA, ElmarghanyA, AlghaithAA, et al.Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism. Br J Haematol, 2025; 206:858–863; doi: 10.1111/bjh.19884
11.
YildirimC. Galectin-3 release in the bone marrow microenvironment promotes drug resistance and relapse in acute myeloid leukemia. Life-Basel, 2025; 15:937; doi: 10.3390/life15060937
12.
ShermanLS, PatelSA, CastilloMD, et al.NFkB targeting in bone marrow mesenchymal stem cell-mediated support of age-linked hematological malignancies. Stem Cell Rev Rep, 2021; 17:2178–2192; doi: 10.1007/s12015-021-10235-6
13.
WuJX, LiXQ, LiuY, et al.MMP14 from BM-MSCs facilitates progression and Ara-C resistance in acute myeloid leukemia via the JAK/STAT pathway. Exp Hematol Oncol, 2025; 14:43; doi: 10.1186/s40164-025-00635-6
14.
SabbahR, SaadiS, Shahar-GabayT, et al.Abnormal adipogenic signaling in the bone marrow mesenchymal stem cells contributes to supportive microenvironment for leukemia development. Cell Commun Signal, 2023; 21:277; doi: 10.1186/s12964-023-01231-z
15.
PourebrahimR, MontoyaRH, AlanizZ, et al.Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage. Cell Death Dis, 2023; 14:371; doi: 10.1038/s41419-023-05844-7
16.
LiuL, LiuH, ChenM, et al.miR-301b∼miR-130b-PPARgamma axis underlies the adipogenic capacity of mesenchymal stem cells with different tissue origins. Sci Rep, 2017; 7:1160; doi: 10.1038/s41598-017-01294-2
17.
KonoplevaM, TabeY, ZengZ, et al.Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches. Drug Resist Updat, 2009; 12:103–113; doi: 10.1016/j.drup.2009.06.001
18.
Kuhestani-DehaghiB, AmirpourM, NabigolM, et al.Evaluating the effect of acute myeloblastic leukemia-derived exosomes on the human bone marrow mesenchymal stromal cell proliferation. Mol Biol Rep, 2024; 52:62; doi: 10.1007/s11033-024-10155-x
19.
CarterBZ, MakPY, WangX, et al.An ARC-regulated IL1beta/Cox-2/PGE2/beta-Catenin/ARC circuit controls leukemia-microenvironment interactions and confers drug resistance in AML. Cancer Res, 2019; 79:1165–1177; doi: 10.1158/0008-5472.CAN-18-0921
20.
SadovskayaA, PetinatiN, ShipounovaI, et al.Damage of the bone marrow stromal precursors in patients with acute leukemia at the onset of the disease and during treatment. Int J Mol Sci, 2024; 25:13285; doi: 10.3390/ijms252413285
21.
BorellaG, Da RosA, BorileG, et al.Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia. Blood, 2021; 138:557–570; doi: 10.1182/blood.2020009845
22.
AzadnivM, MyersJR, McMurrayHR, et al.Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support. Leukemia, 2020; 34:391–403; doi: 10.1038/s41375-019-0568-8
23.
SadovskayaA, PetinatiN, DrizeN, et al.Acute myeloid leukemia causes serious and partially irreversible changes in secretomes of bone marrow multipotent mesenchymal stromal cells. Int J Mol Sci, 2023; 24:8953; doi: 10.3390/ijms241089538953
24.
BurkJ, SassmannA, KasperC, et al.Extracellular matrix synthesis and remodeling by mesenchymal stromal cells is context-sensitive. Int J Mol Sci, 2022; 23:1758; doi: 10.3390/ijms23031758
25.
CorradiG, BassaniB, SimonettiG, et al.Release of IFN-γ by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells. Clinical Cancer Research, 2022; 28:3141–3155; doi: 10.1158/1078-0432.CCR-21-3594
26.
AhmedHMM, NimmagaddaSC, Al-MataryYS, et al.Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells. Br J Haematol, 2022; 196:995–1006; doi: 10.1111/bjh.17940
27.
WangC, SongR, YuanJJ, et al.Exosome-shuttled METTL14 from AML-derived mesenchymal stem cells promotes the proliferation and radioresistance in AML cells by stabilizing ROCK1 expression via an m6A-IGF2BP3-dependent mechanism. Drug Dev Res, 2025; 86:e70025; doi: 10.1002/ddr.70025
28.
LiXY, ZhouQ, HaoXW, et al.Targeting NLRP1-CCL8 axis in the leukaemic niche suppresses AML via inhibition of PI3K-AKT signalling. Br J Haematol, 2025; 207:789–801; doi: 10.1111/bjh.70011
AndersonNR, ShethV, LiH, et al.Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling. Leukemia, 2023; 37:560–570; doi: 10.1038/s41375-022-01798-5
31.
KangL, LiZ, LiF, et al.Transcriptome and proteome analysis identify decorin as a principal antifibrotic component trapping TGF‐β1 within adipose‐derived stem cell secretome. Stem Cells Int, 2025; 2025:1416567; doi: 10.1155/sci/1416567
32.
KamioH, OkabeK, HondaM, et al.Knockdown of decorin in human bone marrow mesenchymal stem cells suppresses proteoglycan layer formation and establishes a pro-inflammatory environment on titanium oxide surfaces. J Mater Sci: Mater Med, 2025; 36:5; doi: 10.1007/s10856-024-06849-0
33.
LiuM, YangQ, ZhangL. Analysis of the influence of serum MMP‐2 and vWF levels on the predictive value of risk grade and prognosis of patients with acute myeloid leukemia. Contrast Media Mol Imaging, 2022; 2022:1865189; doi: 10.1155/2022/1865189
34.
ZhangR, MiaoJ, ZhaiM, et al.BATF promotes extramedullary infiltration through TGF‐β1/Smad/MMPs axis in acute myeloid leukemia. Mol Carcinog, 2024; 63:1146–1159; doi: 10.1002/mc.23715
35.
WangR, XieS, ZhuS, et al.Targeting matrix metallopeptidase 2 by hydroxyurea selectively kills acute myeloid mixed-lineage leukemia. Cell Death Discov, 2022; 8:180; doi: 10.1038/s41420-022-00989-4
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
